ClinicalTrials.gov
ClinicalTrials.gov Menu

Usability of an AI for M923 in Subjects With Moderate to Severe RA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02722044
Recruitment Status : Completed
First Posted : March 29, 2016
Results First Posted : May 1, 2018
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Momenta Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Biological: M923 Device: Autoinjector Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Study Start Date : April 2016
Actual Primary Completion Date : February 21, 2017
Actual Study Completion Date : February 21, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: All Study Participants
All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
Biological: M923
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Other Name: Adalimumab

Device: Autoinjector
Subcutaneous administration




Primary Outcome Measures :
  1. Usability of the Auto-injector (AI) at Week 4 [ Time Frame: Week 4 ]
    The primary usability measure was the participant rating captured in the PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules at Week 4. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.


Secondary Outcome Measures :
  1. Number of Participants With Successful Injections as Assessed by the Observer at Week 4 [ Time Frame: Week 4 ]
    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

  2. Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 4 [ Time Frame: Week 4 ]
    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

  3. Usability of the Auto-injector at Baseline [ Time Frame: Baseline (Day 1) ]
    The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Baseline. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

  4. Usability of the Auto-injector at Week 2 [ Time Frame: Week 2 ]
    The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Week 2. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

  5. Number of Participants With Successful Injections as Assessed by the Observer at Baseline [ Time Frame: Baseline (Day 1) ]
    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

  6. Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline [ Time Frame: Baseline (Day 1) ]
    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

  7. Number of Participants With Successful Injections as Assessed by the Observer at Week 2 [ Time Frame: Week 2 ]
    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

  8. Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 2 [ Time Frame: Week 2 ]
    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

  9. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments [ Time Frame: Baseline; 32 Weeks ]
    Hematology, clinical chemistry, and urinalysis clinical laboratory parameters were assessed. The hematology panel consisted of complete blood count, hemoglobin, hematocrit, mean cell volume, total leukocytes, and platelet counts. The clinical chemistry panel consisted of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase, creatine kinase, C-reactive protein, cholesterol, triglycerides, total protein, sodium, potassium, chloride, blood urea nitrogen, creatinine, albumin, calcium, phosphate, glucose, glycosylated hemoglobin, uric acid, and bicarbonate. The urinalysis panel consisted of leucocytes, protein, bilirubin, urobilinogen, glucose, ketones, blood pH, nitrite, and specific gravity. Clinical significance was assessed by the Investigator.

  10. Number of Participants With Vital Signs Outside the Expected Range [ Time Frame: 32 Weeks ]
    Vital signs included respiratory rate, body temperature, pulse rate, and systolic and diastolic blood pressure.

  11. Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings [ Time Frame: Baseline; 32 Weeks ]
    Clinical significance was assessed by the Investigator.

  12. Number of Participants With Adverse Events Leading to Premature Study Withdrawal [ Time Frame: 32 Weeks ]
    The number of participants who had an adverse event that led to premature study withdrawal was assessed.

  13. Number of Participants With Treatment-emergent Injection Site Reactions [ Time Frame: 32 Weeks ]
    An injection site reaction is defined as pain, tenderness, erythema/redness, induration/swelling, and other. If an injection site reaction was observed, a physician was to characterize and document the reaction as an adverse event (AE). Treatment-emergent adverse events (TEAEs) are defined as AEs that started or worsened in severity on or after the first dose of study medication, until study completion/withdrawal or within 30 days following the last treatment for early withdrawn participants.

  14. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of Anti-drug Antibodies (ADAs) at Baseline [ Time Frame: Baseline (Day 1) ]
    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  15. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 4 [ Time Frame: Week 4 ]
    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  16. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 12 [ Time Frame: Week 12 ]
    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  17. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 24 [ Time Frame: Week 24 ]
    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  18. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at the Safety Follow-Up Visit [ Time Frame: Safety Follow-Up Visit (32 Weeks) ]
    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  19. Immunogenicity of M923 Assessed as the Number of Participants With Neutralizing Anti-drug Antibodies (nADAs) at Baseline [ Time Frame: Baseline (Day 1) ]
    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  20. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 4 [ Time Frame: Week 4 ]
    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  21. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 12 [ Time Frame: Week 12 ]
    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  22. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 24 [ Time Frame: Week 24 ]
    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

  23. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at the Safety Follow-Up Visit [ Time Frame: Safety Follow-Up Visit (32 Weeks) ]
    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants ≥18 years old at the time of Screening
  2. Able to understand and communicate with the Investigator and comply with the requirements of the study, and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
  3. RA diagnosed for at least 6 months before Screening
  4. Meets classification criteria for rheumatoid arthritis (RA) by 2010 American College of Rheumatology/European League Against Rheumatism criteria
  5. Active disease at Screening and Baseline
  6. Participants must have at least 1 documented swollen and/or tender joint in their hand or wrist of the dominant hand as assessed by the Investigator or designated assessor
  7. Must be willing and able to attempt self-administration of subcutaneous (SC) injection(s)
  8. Male participants and their female partners must be willing to comply with the contraception restrictions for this study from the time of the first administration of investigational product (IP) until 3 months after the last dose.
  9. Female participants must have a negative pregnancy test at screening and on admission to the clinic, and must not be lactating and must be using an acceptable method of contraception throughout the study and for 3 months after the last dose, or be of non-childbearing potential. Non-pregnant female partners of male participants who are of childbearing potential should use an effective form of contraception.

Exclusion Criteria:

  1. Prior use of systemic tumor necrosis factor (TNF) inhibitor therapy.
  2. Prior use of rituximab
  3. Prior use of abatacept, tocilizumab and tofacitinib within 4 weeks prior to Screening
  4. Current use of a conventional disease modifying anti-rheumatic drugs (DMARD) other than the following: methotrexate orally (≤25 mg/day), hydroxychloroquine (≤400 mg/day) or sulfasalazine (≤3 g/day)) at a stable dose for at least 4 weeks prior to Screening. If discontinued, methotrexate, hydroxychloroquine, and sulfasalazine must have been discontinued at least 4 weeks prior to Baseline. No other conventional DMARDs are permitted and no combination therapy is permitted.
  5. Prior use of cytotoxic or alkylating agents or immunosuppressants must have been discontinued for at least 90 days prior to Baseline
  6. Current use of oral corticosteroids at a dose >10 mg/day prednisone or equivalent or change of dose within 2 weeks prior to Screening
  7. Current use of more than 1 nonsteroidal anti-inflammatory drug.
  8. Prior use of injectable corticosteroids (intramuscular [IM], intra-articular [IA], or intravenous [IV]) within 6 weeks prior to Baseline
  9. Prior or current use of other self-injected drugs, eg, insulin
  10. All other prior non-RA concomitant treatments must be on a stable dose for at least 4 weeks before Baseline
  11. Meets Class IV Steinbrocker criteria for disability/activities of daily living
  12. Laboratory abnormalities at Screening deemed clinically significant by the Investigator and/or Sponsor.
  13. Presence of fibromyalgia, another autoimmune rheumatologic illness or inflammatory arthritis, eg, systemic lupus erythematosus, gout. The presence of secondary Sjogren's syndrome is permitted.
  14. Joint surgery within the last 8 weeks prior to Screening
  15. Severe, progressive, or uncontrolled renal, hepatic, metabolic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac or neurologic disease, including pleural effusions or ascites, which in the opinion of the Investigator would preclude the participant from adhering to or completing the study or where participation in the study exposes the participant to unfavorable benefit/risk
  16. History or presence of signs and/or symptoms or a diagnosis of a demyelinating disorder
  17. History or presence of Class III or IV New York Heart Association congestive heart failure
  18. History or presence of symptoms suggestive of lymphoproliferative disorders, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma
  19. Existing malignancy or history of any malignancy except adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ, with no more than 3 lifetime basal cell or squamous cell carcinomas
  20. Chronic infections, recurrent infections (3 or more of the same infection requiring anti-infective treatment in any rolling 12-month period); any recent infection (ie, in the last 30 days) requiring hospitalization or any infection requiring parenteral anti-infective therapy within 30 days or oral infective therapies within 14 days of Baseline; herpes zoster within 6 months of Baseline or more than 2 lifetime episodes of herpes zoster; or history of systemic fungal infection or opportunistic infection (eg, coccidioidomycosis, histoplasmosis, toxoplasmosis)
  21. History or presence of human immunodeficiency virus (HIV), Hepatitis B or C virus
  22. History of active tuberculosis (TB) or untreated or inadequately treated latent TB.
  23. Participant has been exposed to an investigational product (IP) within 30 days (or 5 half-lives) prior to enrollment, whichever is longer, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  24. Participant is a family member or employee of the Investigator or Baxalta or its partners

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02722044


Locations
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, North Carolina
Medication Management, LLC
Greensboro, North Carolina, United States, 27408
United States, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Altoona Center for Clinical Research, PC
Duncansville, Pennsylvania, United States, 16635
United States, Texas
Austin Regional Clinic, PA
Austin, Texas, United States, 78731
Accurate Clinical Management
Houston, Texas, United States, 77004
Accurate Clinical Research, Inc.
Houston, Texas, United States, 77034
Sponsors and Collaborators
Momenta Pharmaceuticals, Inc.
Investigators
Study Director: John Caminis, MD Baxalta US Inc., now part of Shire
  Study Documents (Full-Text)

Documents provided by Momenta Pharmaceuticals, Inc.:
Study Protocol  [PDF] August 26, 2016
Statistical Analysis Plan  [PDF] October 19, 2016


Responsible Party: Momenta Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02722044     History of Changes
Other Study ID Numbers: 911502
First Posted: March 29, 2016    Key Record Dates
Results First Posted: May 1, 2018
Last Update Posted: May 16, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Adalimumab
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents
Antirheumatic Agents